Rutgers Startup Hopes Its Potentially Breakthrough Technology Will Improve Alzheimer’s Treatment NanoNewron, Inc., a startup founded based on technology developed at Rutgers, The State University of New Jersey, looks to advance its potentially game changing approach towards treating Alzheimer’s D...

research.rutgers.edu/news/rutgers...
#nanonewron #newrobus #alzheimers #research #biologics #biotech #brainhealth

NanoNewron Appoints Industry Veteran Marco Taglietti, M.D., as Chief Executive Officer to Lead the Company and the Development of Their Promising Alzheimer’s Compound Marco Taglietti, MD is appointed CEO of NanoNewron, a company developing TNF-α inhibitors for Alzheimer’s, engineered to cross the Blood-Brain Barrier...

www.globenewswire.com/news-release...

#nanonewron #newrobus #alzheimer’s #biotech #research #biologics #bloodbrainbarrier #brainhealth

At NanoNewron, we develop biologics that cross the blood-brain barrier to neutralize TNF-α, a key driver of neuroinflammation in Alzheimer’s & neurodegeneration. Our TfR1-mediated transcytosis platform enables targeted TNF-α inhibition to restore brain health.
#NanoNewron #newrobus #biotech